Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo
Bandelow, B., Stein, D.J., Dolberg, O.T., Andersen, H.F. and Baldwin, D.S. (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry, 40, (4), 152-156.
Full text not available from this repository.
Background: It has been argued that measurement of outcome in panic disorder should not be limited to monitoring the number of panic attacks, but should include all domains that affect patient quality of life. Methods: Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life. The subscales of the Panic and Agoraphobia Scale (P&A) (Panic Attacks, Agoraphobic Avoidance, Anticipatory Anxiety, Functional and Social Disability, and Worries about Health) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were analyzed. Results: Treatment with escitalopram was associated with significant improvement on all 5 subscales of the P&A. Citalopram was significantly different from placebo in 3 subscales. Escitalopram and citalopram were significantly better than placebo in improving quality of life (measured by the total score of the Q-LES-Q Scale). Escitalopram was superior to placebo on 12 of 16 items of the Q-LES-Q, while citalopram was superior on 7 items. Conclusion: The P&A scale was more robust than measurement of panic frequency in differentiating medication from placebo. Escitalopram treatment was associated with improvement on all assessed domains that impair quality of life in panic disorder. Measurement of clinical improvement should not be solely based on panic attack frequency, but should also include assessment of a broad range of domains that affect patient quality of life.
|Keywords:||satisfaction, social anxiety disorder, health, placebo, disorders, severity, efficacy, double-blind,agoraphobia, multicenter, dsm-iv, escitalopram, validity, population, major depressive disorder|
|Subjects:||R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
|Date Deposited:||12 Sep 2008|
|Last Modified:||25 Apr 2013 18:25|
|Contributors:||Bandelow, B. (Author)
Stein, D.J. (Author)
Dolberg, O.T. (Author)
Andersen, H.F. (Author)
Baldwin, D.S. (Author)
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)